Clinical Trial Update: A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating SER-287 for adults with active ulcerative colitis was terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• SER-287 (SER-287)

Snippet

Sponsor: Seres Therapeutics, Inc. | Conditions: Ulcerative Colitis | Phase 2 | Status: TERMINATED | Results posted: 2022-06-21